Automation
Merck KGaA to Acquire Rapid Micro Biosystems for $0.75/Share
The deal brings automated microbial testing technology into Merck's pharmaceutical quality-control portfolio as biologics manufacturing grows more complex.
Key takeaways
- Merck KGaA will acquire Rapid Micro Biosystems for $0.75 per share in cash, with closing expected in December 2026.
- The Growth Direct platform automates microbial testing for pharmaceutical manufacturing, delivering faster results than manual methods.
- The acquisition advances Merck's strategic focus on integrated quality-control workflows as biologics and cell therapy production scales.
- Automated systems reduce manual transcription errors and support data integrity requirements in regulated manufacturing.
- The deal builds on a distribution and collaboration agreement the companies signed in February 2025.
Merck KGaA, Darmstadt, Germany has signed a definitive agreement to acquire Rapid Micro Biosystems (Nasdaq: RPID) for $0.75 per share in cash, the companies announced November 16. The transaction would integrate Rapid Micro Biosystems' automated microbial testing platform into Merck's pharmaceutical quality-control business, which operates as MilliporeSigma in the United States and Canada.
The acquisition centers on Rapid Micro Biosystems' Growth Direct platform, which automates microbial quality-control testing for pharmaceutical manufacturers. The system handles sample incubation, imaging, and colony counting without manual intervention, supporting environmental monitoring, water testing, and bioburden analysis.
Why it matters
As pharmaceutical companies scale production of biologics, cell therapies, and gene therapies, quality-control laboratories face mounting pressure to deliver faster results while maintaining data integrity. Automation addresses both demands by reducing manual transcription errors and accelerating time-to-decision. For Merck, the deal advances a strategic shift toward integrated workflow solutions rather than standalone instruments—a positioning move as the life sciences tools market consolidates around end-to-end capabilities.
How the Technology Works
The Growth Direct platform detects microbial growth during incubation rather than waiting for manual inspection after a fixed period. This approach delivers results faster than conventional methods, according to the companies. The system also digitizes sample tracking and results, reducing the manual data entry that can introduce compliance risks in regulated manufacturing environments.
"Quality control is essential to the reliable manufacture of medicines," said Paolo Carli, Head of Advanced Solutions for Merck's Life Science business. "Our customers need reliable results faster, more efficient quality-control workflows and robust data integrity to support regulatory compliance."
Strategic Context
The acquisition builds on a global distribution and collaboration agreement the companies announced in February 2025. Merck's existing quality-control portfolio spans environmental monitoring, in-process testing, and release testing. Adding automated microbial detection and data-management capabilities aligns with the company's mid- to long-term strategic focus on integrated workflows.
Robert Spignesi, President and CEO of Rapid Micro Biosystems, said joining Merck would enable the company to "combine our expertise in automation with a broader range of quality-control workflow solutions."
Transaction Timeline
The deal is expected to close in December 2026, subject to standard closing conditions including the tender of shares representing at least a majority of Rapid Micro Biosystems' outstanding voting shares. Merck generated €21.1 billion in sales across 65 countries in 2025 and employs more than 62,000 people globally.
The transaction details were first reported by Merck KGaA, Darmstadt, Germany in a press release distributed through Globe Newswire.